Abstract:OBJECTIVES:With the decreased protective effect of Bacille Calmette-Guérin (BCG) vaccine, widespread drug-resistant strains of tuberculosis as well as the lack of effective vaccines, global morbidity and mortality of tuberculosis remains high. The purpose of this study is to evaluate the potential of Mycobacterium tuberculosis antigen Rv2654 as a candidate vaccine against tuberculosis, and to verify the characteristics of cellular and humoral immune responses in mice induced by this protein.METHODS:Isopropyl-beta-D-thiogalactoside (IPTG) was added to induce the expression of Rv2654 recombinant protein in the logarithmic growth stage of bacteria. The recombinant protein was purified by affinity chromatography and identified by Western blotting. The immunoreactivity of Rv2654 recombinant protein with human sera was detected by ELISA. After immunization with Rv2654 recombinant protein, the levels of Th1/Th2 cytokines in peripheral blood of mice was measured using cytokine magnetic bead arrays, and the T and B lymphocyte subsets in spleen of mice was analyzed by flow cytometry.RESULTS:The recombinant protein Rv2654 was successfully induced and expressed. The ELISA data showed that the recombinant protein Rv2654 was responsive to the serum of BCG-inoculated patients or active pulmonary tuberculosis patients. In immunized mice with recombinant protein Rv2654, the expression of IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10 and other cytokines in peripheral blood was elevated (all P<0.05). Flow cytometry analysis showed that the recombinant protein significantly stimulated the differentiation of CD4+T cells and CD8+T cells into effector T cells, and this effect was more obvious when combined with BCG. The recombinant protein Rv2654 also stimulated the activation and proliferation of B cells and their differentiation into memory cells. However, less plasma cells were produced.CONCLUSIONS:Rv2654 protein could induce the cell immune responses and it has good binding ability with serum of BCG-inoculated patients and active pulmonary tuberculosis patients, suggesting that it may serve as a good candidate antigen for tuberculosis immunological prophylaxis and diagnostic vaccines.

Evaluation of a Recombinant BCG Expressing Antigen Ag85B and PPE Protein Rv3425 from DNA Segment RD11 of Mycobacterium Tuberculosis in C57BL/6 Mice

Evaluation Of A New Recombinant Bcg Which Contains Mycobacterial Antigen Ag85b-Mpt64(190-198)-Mtb8.4 In C57/Bl6 Mice

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Rv3620c Elicits Specific Th1 Immune Responses in C57bl/6 Mice

Cpg7909 Adjuvant Enhanced Immunogenicity Efficacy In Mice Immunized With Esat6-Ag85a Fusion Protein, But Does Not Confer Significant Protection Against Mycobacterium Tuberculosis Infection

Protective efficacy of a recombinant BCG secreting antigen 85B/Rv3425 fusion protein against Mycobacterium tuberculosis infection in mice.

Novel Recombinant Bcg Coexpressing Ag85b, Esat-6 And Rv2608 Elicits Significantly Enhanced Cellular Immune And Antibody Responses In C57bl/6 Mice

Recombinant Bcg Coexpressing Ag85b, Esat-6 and Mouse-Ifn-Gamma Confers Effective Protection Against Mycobacterium Tuberculosis in C57bl/6 Mice

Recombinant Bacille Calmette-Guérin coexpressing Ag85B-IFN-γ enhances the cell-mediated immunity in C57BL/6 mice.

More vaccine efficacy studies on the recombinant bacille calmette-guerin co-expressing Ag85B, Mpt64 190-198 and Mtb8.4

Immunogenicity Analysis of a Recombinant BCG Vaccine Strain Overexpressing Rv3478 Protein

More vaccine efficacy studies on the recombinant Bacille Calmette-Guerin co-expressing Ag85B, Mpt64 and Mtb8.4.

Immune Responses and Protective Efficacy Induced by 85B Antigen and Early Secreted Antigenic Target-6 Kda Antigen Fusion Protein Secreted by Recombinant Bacille Calmette-Guérin

Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response.

Dose of Incorporated Immunodominant Antigen in Recombinant BCG Impacts Modestly on Th1 Immune Response and Protective Efficiency Against Mycobacterium Tuberculosis in Mice

Recombinant BCG vaccine expressing multistage antigens of Mycobacterium tuberculosis provides long-term immunity against tuberculosis in BALB/c mice

Expression and Purification of Rv2654 Recombinant Protein from Mycobacterium Tuberculosis and Its Characteristics of Immune Response.

Recombinant BCG::Rv2645 Elicits Enhanced Protective Immunity Compared to BCG in Vivo with Induced ISGylation-related Genes and Th1 and Th17 Responses

PPE Protein (rv3425) from DNA Segment RD11 of Mycobacterium Tuberculosis: a Novel Immunodominant Antigen of Mycobacterium Tuberculosis Induces Humoral and Cellular Immune Responses in Mice.

Novel Recombinant Bcg Coexpressing Ag85b, Esat-6 and Mouse Tnf-Alpha Induces Significantly Enhanced Cellular Immune and Antibody Responses in C57bl/6 Mice

Recombinant BCG::Rv2645 elicits enhanced protective immunity compared to BCG in vivo with induced ISGylation-related genes and Th1 and Th17 responses.

Recombinant BCG Prime and PPE Protein Boost Provides Potent Protection Against Acute Mycobacterium Tuberculosis Infection in Mice